Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development

References

• Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Disposit 33:1637–47.
   PubMed Web of Science ®Google Scholar
• Bachmann KA, Lewis JD. (2005). Predicting inhibitory drug–drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064–72.
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Disposit 31:289–93.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, and Wrighton SA. (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Disposit 31:815–32.
   PubMed Web of Science ®Google Scholar
• Crespi CL, Stresser DM. (2000). Fluorometric screening for metabolism-based drug–drug interactions. J Pharmacol Toxicol Meth 44:325–31.
   PubMed Web of Science ®Google Scholar
• Desta Z, Soukhova NV, Flockhart DA. (2001). Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agent Chemother 45:382–92.
   PubMed Web of Science ®Google Scholar
• Ernest CSII, Hall SD, Jones DR. (2005). Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583–91.
   PubMed Web of Science ®Google Scholar
• Hara Y, Nakajima M, Miyamoto KI, Yokoi T. (2005). Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions. Xenobiotica 35:549–60.
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, Itoh T. (2003). Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Disposit 31:945–54.
   PubMed Web of Science ®Google Scholar
• Lim HK, Duczak NJr, Brougham L, Elliot M, Patel K, Chan K. (2005). Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Disposit 33:1211–19.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. (1998). Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361–90.
   PubMed Web of Science ®Google Scholar
• Madeira M, Levine M, Chang TK, Mirfazaelian A, Bellward GD. (2004). The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Disposit 32:460–7.
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. (2000). An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Disposit 28:1031–7.
   PubMed Web of Science ®Google Scholar
• McConn DJII, Lin YS, Allen K, Kunze KL, Thummel KE. (2004). Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite–inhibitor complex-forming drugs. Drug Metab Disposit 32:1083–91.
   PubMed Web of Science ®Google Scholar
• Murray M. (1997). Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 24:465–70.
   PubMed Web of Science ®Google Scholar
• Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, Lin CC. (2001). Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Disposit 29:748–53.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug–drug interactions. Drug Metab Disposit 35:246–55.
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. (2000). Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244–53.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Elliot DJ, Lewis BC, Miners JO. (2004). Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996–1007.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO. (2006). An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61:570–84.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Miners JO. (2008). Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 65:87–97.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, Baillie TA. (1999). Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol 47:291–8.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23.
   PubMed Web of Science ®Google Scholar
• Smith DA, Abel SM, Hyland R, Jones BC. (1998). Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 28:1095–128.
   PubMed Web of Science ®Google Scholar
• Teng R, Sarich TC, Eriksson UG, Hamer JE, Gillette S, Schutzer KM, Carlson GFJr, Kowey PR. (2004). A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol 44:1063–71.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS. (2005). In vitro–in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Disposit 33:845–52.
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. (2004). Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Disposit 32:259–66.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo K. (2007). Risk assessment for drug–drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Disposit 35:1232–8.
   PubMed Web of Science ®Google Scholar
• Wen X, Wang JS, Neuvonen PJ, Backman JT. (2002). Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 57:799–804.
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Disc 4:825–33.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suzuki A, Kohno Y. (2004). High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 34:87–101.
   PubMed Web of Science ®Google Scholar
• Zhao P, Kunze KL, Lee CA. (2005). Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Disposit 33:853–61.
   PubMed Web of Science ®Google Scholar
• Zhi J, Moore R, Kanitra L, Mulligan TE. (2003). Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol 43:428–35.
   PubMed Web of Science ®Google Scholar